• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

    10/17/24 11:31:06 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCUS alert in real time by email
    SC 13G/A 1 Arcus_Biosciences_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    ARCUS BIOSCIENCES INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    03969F109

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    03969F109 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,838,691

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,011,174

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,011,174.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.3%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    03969F109 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      ARCUS BIOSCIENCES INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      3928 POINT EDEN WAY HAYWARD CA 94545 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      03969F109

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    03969F109 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 3,011,174.00  
      (b) Percent of class: 3.3%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 2,838,691
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 3,011,174
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ý
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    03969F109 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $RCUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCUS

    DatePrice TargetRatingAnalyst
    2/26/2025$18.00 → $24.00Neutral → Buy
    H.C. Wainwright
    10/21/2024$20.00Neutral
    H.C. Wainwright
    10/8/2024$29.00Overweight
    Wells Fargo
    11/18/2022$33.00Neutral
    BofA Securities
    10/11/2022$40.00Overweight
    Morgan Stanley
    11/19/2021$42.00 → $53.00Buy
    Citigroup
    11/19/2021$48.00 → $60.00Overweight
    Barclays
    11/18/2021$68.00 → $100.00Outperform
    SVB Leerink
    More analyst ratings

    $RCUS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Arcus Biosciences Inc.

      SCHEDULE 13G - Arcus Biosciences, Inc. (0001724521) (Subject)

      5/13/25 5:57:37 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Arcus Biosciences Inc.

      10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)

      5/6/25 4:12:08 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Arcus Biosciences, Inc. (0001724521) (Filer)

      5/6/25 4:09:59 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

      SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      12/17/24 9:52:58 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

      SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      11/12/24 9:50:12 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

      SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      10/17/24 11:31:06 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:06:05 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:05:56 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gilead Sciences, Inc. bought $14,999,996 worth of shares (1,363,636 units at $11.00), increasing direct ownership by 5% to 31,424,760 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/20/25 7:42:29 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock at an exercise price per share of $12.45, which was the closing price on February 10, 2025, and restricted stock units to acquire a total of 75,193 shares of the Company's common stock. In addition to the awards to Dr. Markus, the Co

      2/11/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

      Dr. Markus will oversee Arcus's clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies   Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus's responsibilities will include oversight of Arcus's clinical development

      1/21/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo

      8/24/22 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $RCUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $RCUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RCUS
    Financials

    Live finance-specific insights

    See more
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,250 shares of the Company's common stock at an exercise price per share of $8.53, which was the closing price on May 8, 2025, and restricted stock units to acquire a total of 10,650 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2

      5/9/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

      Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Additional data from the ARC-20 cohorts evaluating casdatifan monotherapy in patients who had progressed on both an anti-PD-1 and a tyrosine kinase inhibitor (TKI) therapy are expected in the fall Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in the second quarter of 2025 Arcus is well positioned

      5/6/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 39,750 shares of the Company's common stock at an exercise price per share of $8.11, which was the closing price on April 23, 2025 and restricted stock units to acquire a total of 19,950 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2

      4/24/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:06:05 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:05:56 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gilead Sciences, Inc. bought $14,999,996 worth of shares (1,363,636 units at $11.00), increasing direct ownership by 5% to 31,424,760 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/20/25 7:42:29 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Arcus Biosciences from Neutral to Buy and set a new price target of $24.00 from $18.00 previously

      2/26/25 7:16:55 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Arcus Biosciences with a new price target

      H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00

      10/21/24 7:58:13 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Arcus Biosciences with a new price target

      Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00

      10/8/24 7:34:04 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

      Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Additional data from the ARC-20 cohorts evaluating casdatifan monotherapy in patients who had progressed on both an anti-PD-1 and a tyrosine kinase inhibitor (TKI) therapy are expected in the fall Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in the second quarter of 2025 Arcus is well positioned

      5/6/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

      New data from the Phase 1/1b ARC-20 cohort evaluating HIF-2a inhibitor casdatifan in combination with cabozantinib in clear cell renal cell carcinoma (ccRCC) will be presented in an oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The ASCO presentation will include a more mature data cut than that described in the abstract and will include safety and initial efficacy data for the 100mg casdatifan once-daily (QD) plus 60mg cabozantinib QD cohort Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing diff

      4/23/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

      Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Tuesday, May 6th, 2025 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2025. Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 762544. Participants may also register for the call online using the following link: https://events.q4inc.com/attendee

      4/22/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care